Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease... see more

TSX:SZLS - Post Discussion

StageZero Life Sciences Ltd > True Value Of Stagezero Stock Price?
View:
Post by Vidkid777 on Jan 23, 2021 5:20pm

True Value Of Stagezero Stock Price?

Can someone with more intelligence wrt to stock pricing let us know why the true valie
of Stagezero stock should be trading at.  I think based on interviews with Tripp it is safe to say revenue should be equal to or greater than the last quarterly revenue reported.  Just hoping someone here can provide a true price evaluation with no fluff or what ifs.....just assume q4 revenue = Q3 revenue in the calculation......much appreciated in advance!
Comment by LionWhisperer on Jan 23, 2021 5:28pm
This post has been removed in accordance with Community Policy
Comment by LithLover on Jan 23, 2021 5:47pm
The average in the industry is 14x revenue.  Other factors such as cash on hand, buildings, other assets etc can be factored in.  Let's assume a low multiple at 10x revenues If you look at Q3 and Tripp is saying revenue is on an upwards trajectory.  Assume $3-4 million/quarter as conservative.  $12-16 a year. $120-$160 valuation for a share price equivalent of $2.00-2.66  ...more  
Comment by capebretongirl on Jan 23, 2021 5:49pm
$1.13 is the valuation - simple as that. This is all that matters as its currently what the investment community has deemed us to be worth. Clarus has a speculative $4.00 price tag but that means nothing as its a year away. Covid revenue coupled with the yet uncertainty of Aristotle's roll out will dictate our future sp.  If all goes swellingly over the next 11 months then we can expect ...more  
Comment by jp1989 on Jan 23, 2021 6:04pm
yes covid is here to stay !!! the world is just too stupid not to infect themselves and the vaccine will not work. but I agree with aristotle
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities